The U.S. Food and Drug Administration announced it will relax certain rules for approving low-cost versions of some high-priced medications to reduce costs.
(Reuters) -AbbVie said on Friday the Trump administration was pushing for steeper cuts in this year's Medicare drug price ...
FRIDAY, Oct. 31, 2025 (HealthDay News) — The U.S. Food and Drug Administration (FDA) announced Wednesday that it will relax ...
The steady approval of new biosimilars in recent years provides additional safe, effective, and cost-effective options for ...
India Today on MSN
Shot in the arm for Indian drugmakers as US FDA moves to ease biosimilar approvals
A proposed move by the US Food and Drug Administration (FDA) to accelerate development and ease approval of biosimilars could ...
AbbVie raised its earnings guidance for 2025 and added to its quarterly dividend after another strong quarter of revenue ...
Skyrizi and Rinvoq sold nearly seven billion dollars, almost half of the company’s income for the quarter alone.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback